Metrion Biosciences launches NaV1.9 high-throughput screening assay to strengthen screening portfolio and advance research on new medicines for pain
- Validated drug discovery assay overcomes previous challenges in targeting NaV1.9 ion channels for chronic pain signalling
- Completes unique suite of rapid, scalable pain-related sodium channel assays and services to accelerate hit-to-lead and lead optimisation programmes